{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:20:00Z","timestamp":1788272400640,"version":"build-2803163510"},"reference-count":227,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":1735,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1111\/j.1469-0691.2010.03135.x","type":"journal-article","created":{"date-parts":[[2010,2,11]],"date-time":"2010-02-11T15:30:18Z","timestamp":1265902218000},"page":"3-30","source":"Crossref","is-referenced-by-count":37,"special_numbering":"S1","title":["A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice"],"prefix":"10.1016","volume":"16","author":[{"given":"M.","family":"Dryden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.T.","family":"Andrasevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cornaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Giamarellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.C.","family":"Gyssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Nathwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Voss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 5","key":"10.1111\/j.1469-0691.2010.03135.x_bib1","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1086\/533590","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus","volume":"46","author":"Boucher","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0924-8579(09)70541-2","article-title":"Skin and soft tissue infection: microbiology and epidemiology","volume":"34","author":"Dryden","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib3","author":"European Antimicrobial Resistance Surveillance System"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib4","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/QCO.0b013e3283013add","article-title":"Methicillin-resistant Staphylococcus aureus control in the 21st century: beyond the acute care hospital","volume":"21","author":"Navarro","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-0691.2009.02701.x","article-title":"Management of methicillin-resistant Staphylococcus aureus infections","volume":"15","author":"Garau","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib6","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib7","author":"Centers for Disease Control an dPrevention"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib8","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1086\/590937","article-title":"Health care-associated infection (HAI): a critical appraisal of the emerging threat\u2013-proceedings of the HAI Summit","volume":"47","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2010.03135.x_bib9","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1086\/526355","article-title":"Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes\u2013-proceedings of the HCAP Summit","volume":"46","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1155\/2004\/531434","article-title":"The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: a CIDS\/CAMM position paper","volume":"15","author":"Simor","year":"2004","journal-title":"Can J Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib11","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jac\/dkp065","article-title":"Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom","volume":"63","author":"Gould","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jac\/dkn162","article-title":"Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy","volume":"62","author":"Masterton","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/jac\/dkn096","article-title":"Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community","volume":"61","author":"Nathwani","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib14","first-page":"234","article-title":"Guidelines for the treatment on infections caused by methicillin-resistant Staphylococcus aureus [in Spanish]","volume":"21","author":"Mensa","year":"2008","journal-title":"Rev Esp Quimioter"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib15","first-page":"7","article-title":"Guidelines for prevention, control and treatment of infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [Croatian]","volume":"130","author":"Kalenic","year":"2008","journal-title":"Lijec Vjesn"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1469-0691.2009.02700.x","article-title":"New insights concerning methicillin-resistant Staphylococcus aureus disease","volume":"15","author":"Cauda","year":"2009","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 13","key":"10.1111\/j.1469-0691.2010.03135.x_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1157\/13128776","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus [Spanish]","volume":"26","author":"Cercenado","year":"2008","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1469-0691.2003.00698.x","article-title":"Epidemiology of methicillin-resistant staphylococci in Europe","volume":"9","author":"Stefani","year":"2003","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib19","series-title":"Oxford textbook of medicine","first-page":"470","article-title":"Staphylococci","author":"Eykyn","year":"2005"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S1473-3099(09)70133-1","article-title":"Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia","volume":"9","author":"Hidron","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0195-6701(88)90055-2","article-title":"Sources and outcome for methicillin-resistant Staphylococcus aureus bacteraemia","volume":"11","author":"Cafferkey","year":"1988","journal-title":"J Hosp Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib22","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/S0924-8579(07)70085-7","article-title":"Community-onset MRSA bacteraemia: characteristics of patients presenting to hospital","volume":"29","author":"Pearson","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jhin.2007.01.013","article-title":"Prevalence and risk factors for meticillin-resistant Staphylococcus aureus in adult emergency admissions\u2013-a case for screening all patients?","volume":"66","author":"Gopal","year":"2007","journal-title":"J Hosp Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/0003-4819-148-6-200803180-00003","article-title":"Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals","volume":"148","author":"Robicsek","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib25","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1086\/375057","article-title":"Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia","volume":"36","author":"Lodise","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib26","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0140-6736(04)17100-6","article-title":"Oral amoxicillin versus injectable penicillin for severe pneumonia in children aged 3 to 59 months: a randomised multicentre equivalency study","volume":"364","author":"Addo-Yobo","year":"2004","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib27","first-page":"48","article-title":"Oral therapy for pneumonia: Who, When, and With What?","volume":"6","author":"Schmitt","year":"1999","journal-title":"JCOM"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.amjsurg.2005.01.011","article-title":"Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA\u2013-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"189","author":"Sharpe","year":"2005","journal-title":"Am J Surg"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/jac\/dkl283","article-title":"Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus","volume":"58","author":"Kaka","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib30","doi-asserted-by":"crossref","first-page":"s29","DOI":"10.1089\/sur.2008.065.supp","article-title":"Treatment options for uncomplicated community-acquired skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus: oral antimicrobial agents","volume":"9","author":"Zervos","year":"2008","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib31","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1592\/phco.27.2.227","article-title":"Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections","volume":"27","author":"Drew","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib32","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jac\/dkl017","article-title":"Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK","volume":"57","author":"Gemmell","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2010.03135.x_bib33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1469-0691.2005.01162.x","article-title":"Methicillin-resistant Staphylococcus aureus: clinical manifestations and antimicrobial therapy","volume":"11","author":"Cunha","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim\u2013sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/jac\/42.1.107","article-title":"The effect of intravenous-to-oral switch guidelines on the use of parenteral antimicrobials in medical wards","volume":"42","author":"Laing","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib36","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/qjmed\/hci114","article-title":"Pharmacy-implemented guidelines on switching from intravenous to oral antibiotics: an intervention study","volume":"98","author":"McLaughlin","year":"2005","journal-title":"Q J Med"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0163-4453(98)92732-3","article-title":"Sequential antibiotic therapy: the right patient, the right time and the right outcome","volume":"37","author":"Davey","year":"1998","journal-title":"J Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib38","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1185\/03007990802550679","article-title":"Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: a systematic review of randomized controlled trials","volume":"24","author":"Vouloumanou","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib39","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2334-6-94","article-title":"A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay","volume":"6","author":"Desai","year":"2006","journal-title":"BMC Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib40","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/archinte.1995.00430110069007","article-title":"Staphylococcus aureus catheter-associated bacteremia. Minimal effective therapy and unusual infectious complications associated with arterial sheath catheters","volume":"155","author":"Malanoski","year":"1995","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/clinids\/14.1.75","article-title":"Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review","volume":"14","author":"Raad","year":"1992","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib42","doi-asserted-by":"crossref","first-page":"304","DOI":"10.7326\/0003-4819-119-4-199308150-00010","article-title":"Short-course therapy of catheter-related Staphylococcus aureus bacteremia: a meta-analysis","volume":"119","author":"Jernigan","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib43","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1001\/archinte.162.1.25","article-title":"Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases","volume":"162","author":"Jensen","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib44","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","article-title":"Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial","volume":"290","author":"Chastre","year":"2003","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib45","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/01.CCM.0000059313.31477.2C","article-title":"Factors predicting ventilator-associated pneumonia recurrence","volume":"31","author":"Combes","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/01.CCM.0000249826.81273.E4","article-title":"Early predictors for infection recurrence and death in patients with ventilator-associated pneumonia","volume":"35","author":"Combes","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib47","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1164\/ajrccm.150.6.7952612","article-title":"Ventilator-associated pneumonia by Staphylococcus aureus. Comparison of methicillin-resistant and methicillin-sensitive episodes","volume":"150","author":"Rello","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib48","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/01.CCM.0000178180.61305.1D","article-title":"Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides","volume":"33","author":"Rello","year":"2005","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib49","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1378\/chest.08-0011","article-title":"Early microbiological response to linezolid vs. vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus","volume":"134","author":"Wunderink","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib51","first-page":"471","article-title":"Recommendations for the treatment of severe in-hospital pneumonia. Spanish Society of Critical, Coronary, and Intensive Medicine. Spanish Society for Respiratory Tract Pathology. Spanish Society of Infectious Diseases and Clinical Microbiology [Spanish]","volume":"22","author":"Jorda","year":"2004","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib52","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jcrc.2007.12.008","article-title":"Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment","volume":"23","author":"Muscedere","year":"2008","journal-title":"J Crit Care"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00134-008-1336-9","article-title":"Defining, treating and preventing hospital acquired pneumonia: European perspective","volume":"35","author":"Torres","year":"2009","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/jac\/38.5.865","article-title":"Penetration of vancomycin into human lung tissue","volume":"38","author":"Cruciani","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/AAC.37.2.281","article-title":"Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients","volume":"37","author":"Lamer","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib56","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1086\/588160","article-title":"Development of a guideline for the management of ventilator-associated pneumonia based on local microbiologic findings and impact of the guideline on antimicrobial use practices","volume":"29","author":"Dellit","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib57","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jama.1996.03530270074035","article-title":"Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. A challenge to hospital leadership","volume":"275","author":"Goldmann","year":"1996","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib58","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1378\/chest.125.5.1791","article-title":"A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia","volume":"125","author":"Micek","year":"2004","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib59","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/01.CCM.0000055380.86458.1E","article-title":"Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome","volume":"31","author":"Luna","year":"2003","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib60","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1164\/rccm.200406-746OC","article-title":"Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia","volume":"171","author":"Luyt","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1378\/chest.07-2020","article-title":"Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization","volume":"133","author":"Vidaur","year":"2008","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib62","doi-asserted-by":"crossref","first-page":"128","DOI":"10.7326\/0003-4819-133-2-200007180-00012","article-title":"Cultural and economic factors that (mis)- shape antibiotic use: the nonpharmacologic basis of therapeutics","volume":"133","author":"Avorn","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib63","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/QCO.0b013e3283118932","article-title":"Decision support systems for antibiotic prescribing","volume":"21","author":"Sintchenko","year":"2008","journal-title":"Curr Opin Infect Dis"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib64","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.ijantimicag.2007.06.035","article-title":"The TREAT project: decision support and prediction using causal probabilistic networks","volume":"30","author":"Leibovici","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib65","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1001\/jama.294.18.2305","article-title":"Clinical decision support and appropriateness of antimicrobial prescribing: a randomized trial","volume":"294","author":"Samore","year":"2005","journal-title":"JAMA"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib66","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1086\/501875","article-title":"Development of minimum criteria for the initiation of antibiotics in residents of long-term-care facilities: results of a consensus conference","volume":"22","author":"Loeb","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib67","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/archpedi.154.4.386","article-title":"Clinical decision rule to identify febrile young girls at risk for urinary tract infection","volume":"154","author":"Gorelick","year":"2000","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib68","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1136\/pgmj.2005.035113","article-title":"Is antibiotic resistance a problem? A practical guide for hospital clinicians","volume":"81","author":"Barlow","year":"2005","journal-title":"Postgrad Med J"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib69","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/jac\/dkl137","article-title":"Antimicrobial prescribing policy and practice in Scotland: recommendations for good antimicrobial practice in acute hospitals","volume":"57","author":"Nathwani","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2010.03135.x_bib70","doi-asserted-by":"crossref","first-page":"S260","DOI":"10.1086\/598185","article-title":"Clinical consensus conference: survey on Gram-positive bloodstream infections with a focus on Staphylococcus aureus","volume":"48","author":"Naber","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib71","author":"Scottish Medicines Consortium"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib72","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1185\/03007990802442695","article-title":"Self-reported healthcare decision-makers' attitudes towards economic evaluations of medical technologies","volume":"24","author":"Galani","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib73","first-page":"ii37","article-title":"Impact of methicillin-resistant Staphylococcus aureus infections on key health economic outcomes: does reducing the length of hospital stay matter?","volume":"51","author":"Nathwani","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib74","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/ajhp\/58.18.1756","article-title":"Factors influencing physicians' decision to discharge hospitalized patients infected with methicillin-resistant Staphylococcus aureus","volume":"58","author":"Yaldo","year":"2001","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib75","first-page":"71","article-title":"Cost considerations in the evaluation of new therapies for gram-positive bacteria","volume":"13","author":"Nathwani","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib76","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3201\/eid0702.010228","article-title":"Economic impact of antimicrobial resistance","volume":"7","author":"McGowan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib77","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1517\/14656566.9.6.987","article-title":"Pharmacoeconomics of linezolid","volume":"9","author":"Grau","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib78","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ajic.2005.04.246","article-title":"Systematic review of economic analyses of health care-associated infections","volume":"33","author":"Stone","year":"2005","journal-title":"Am J Infect Control"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib79","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/01.CCM.0000104110.74657.25","article-title":"Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin","volume":"32","author":"Shorr","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib80","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1086\/420939","article-title":"Practice guidelines for outpatient parenteral antimicrobial therapy. IDSA guidelines","volume":"38","author":"Tice","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1469-0691.2000.00113.x","article-title":"Advisory group on Home-based and Outpatient Care (AdHOC): an international consensus statement on non-inpatient parenteral therapy","volume":"6","author":"Nathwani","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib82","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/508456","article-title":"Experience of infectious diseases consultants with outpatient parenteral antimicrobial therapy: results of an emerging infections network survey","volume":"43","author":"Chary","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib83","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1093\/jac\/dkm210","article-title":"Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to selfadminister at home? A retrospective analysis of a large cohort over 13 years","volume":"60","author":"Matthews","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib84","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jac\/dkp245","article-title":"Developments in outpatient parenteral antimicrobial therapy (OPAT) for Gram-positive infections in Europe, and the potential impact of daptomycin","volume":"64","author":"Nathwani","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib85","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1469-0691.2000.00112.x","article-title":"Outpatient and home parenteral antibiotic therapy (OHPAT) in the UK: survey of infection specialists' experience and views","volume":"6","author":"Seaton","year":"2000","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 4","key":"10.1111\/j.1469-0691.2010.03135.x_bib86","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1086\/314079","article-title":"Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients","volume":"31","author":"Kollef","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib87","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1073\/pnas.94.22.12106","article-title":"Evaluating treatment protocols to prevent antibiotic resistance","volume":"94","author":"Bonhoeffer","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib88","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/dkn513","article-title":"Impact of biofilm on the in vitro activity of vancomycin alone and in combination with tigecycline and rifampicin against Staphylococcus aureus","volume":"63","author":"Rose","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib89","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1128\/AAC.22.5.903","article-title":"Synergism between vancomycin and gentamicin or tobramycin for methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains","volume":"22","author":"Watanakunakorn","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib90","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib91","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1128\/AAC.00232-06","article-title":"Successful therapy of experimental endocarditis caused by vancomycin-resistant Staphylococcus aureus with a combination of vancomycin and beta-lactam antibiotics","volume":"50","author":"Fox","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib92","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1128\/AAC.00047-09","article-title":"Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin","volume":"53","author":"John","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib93","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/jac\/dkg440","article-title":"Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis","volume":"52","author":"Drinkovic","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib94","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib95","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib96","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.00300-08","article-title":"Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus","volume":"52","author":"Riedel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib97","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib98","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1086\/600295","article-title":"Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem","volume":"49","author":"Jang","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib99","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1086\/499365","article-title":"Dumb and dumber\u2013-the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus","volume":"42","author":"Howden","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib100","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.19.6.1089","article-title":"Interaction between vancomycin and rifampin against Staphylococcus aureus","volume":"19","author":"Watanakunakorn","year":"1981","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib101","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1128\/AAC.40.3.701","article-title":"Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet\u2013fibrin clots","volume":"40","author":"Palmer","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1592\/phco.20.7.673.35166","article-title":"Comparative in vitro activity of vancomycin and levofloxacin in combination with rifampin against planktonic versus sessile cells of Staphylococcus epidermidis","volume":"20","author":"Kang-Birken","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib103","first-page":"73","article-title":"Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin","volume":"82","author":"Henry","year":"1987","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib104","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1128\/AAC.34.6.1014","article-title":"Comparative efficacies of ciprofloxacin, pefloxacin, and vancomycin in combination with rifampin in a rat model of methicillin-resistant Staphylococcus aureus chronic osteomyelitis","volume":"34","author":"Dworkin","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/infdis\/151.1.157","article-title":"Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro\u2013in vivo correlations","volume":"151","author":"Bayer","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib106","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/archinte.168.8.805","article-title":"Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature","volume":"168","author":"Perlroth","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib107","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1128\/AAC.49.7.2735-2745.2005","article-title":"Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations","volume":"49","author":"Tsuji","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib108","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1128\/AAC.39.10.2289","article-title":"Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis","volume":"39","author":"Perdikaris","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib109","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1128\/AAC.40.6.1534","article-title":"Vancomycin\u2013gentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus","volume":"40","author":"Mulazimoglu","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib110","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.41.11.2497","article-title":"Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin\u2013platelet clots in an in vitro infection model","volume":"41","author":"Houlihan","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib111","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0022-3476(87)80533-4","article-title":"Nephrotoxicity of vancomycin\u2013gentamicin therapy in pediatric patients","volume":"110","author":"Swinney","year":"1987","journal-title":"J Pediatr"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib112","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/jac\/25.4.679","article-title":"Nephrotoxicity of vancomycin, alone and with an aminoglycoside","volume":"25","author":"Rybak","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib113","doi-asserted-by":"crossref","first-page":"496","DOI":"10.7326\/0003-4819-97-4-496","article-title":"Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study","volume":"97","author":"Korzeniowski","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib114","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jac\/32.2.325","article-title":"Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination","volume":"32","author":"Goetz","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0773.1992.tb00516.x","article-title":"Chrononephrotoxicity in rat of a vancomycin and gentamicin combination","volume":"71","author":"Fauconneau","year":"1992","journal-title":"Pharmacol Toxicol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib116","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3109\/08860229709026256","article-title":"Nephrotoxicity of gentamicin and vancomycin given alone and in combination as determined by enzymuria and cortical antibiotic levels in rats","volume":"19","author":"Fauconneau","year":"1997","journal-title":"Ren Fail"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib117","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0022-3476(85)80383-8","article-title":"Vancomycin\/aminoglycoside nephrotoxicity","volume":"106","author":"Dean","year":"1985","journal-title":"J Pediatr"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib118","doi-asserted-by":"crossref","first-page":"789","DOI":"10.7326\/0003-4819-90-5-789","article-title":"Single or combination therapy of staphylococcal endocarditis in intravenous drug abusers","volume":"90","author":"Abrams","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/11.1.21","article-title":"In-vitro effects of vancomycin, rifampicin, and fusidic acid, alone and in combination, against methicillin-resistant Staphylococcus aureus","volume":"11","author":"Foldes","year":"1983","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib120","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1128\/AAC.37.11.2466","article-title":"Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"37","author":"Fantin","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib121","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1093\/jac\/34.6.899","article-title":"In-vitro antibacterial activity of fusidic acid alone and in combination with other antibiotics against methicillin-sensitive and -resistant Staphylococcus aureus","volume":"34","author":"Drugeon","year":"1994","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib122","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0924-8579(98)00075-2","article-title":"Fusidic acid in the treatment of methicillin-resistant Staphylococcus aureus","volume":"12","author":"Whitby","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib123","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/S0924-8579(98)00070-3","article-title":"Fusidic acid in septicaemia and endocarditis","volume":"12","author":"Whitby","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib124","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0924-8579(98)00072-7","article-title":"Resistance to fusidic acid","volume":"12","author":"Turnidge","year":"1999","journal-title":"Int J AntimicrobAgents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib125","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0732-8893(99)00116-9","article-title":"Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains","volume":"36","author":"Chang","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib126","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/BF01708239","article-title":"Effect of different combinations of sparfloxacin, oxacillin, and fosfomycin against methicillin-resistant staphylococci","volume":"16","author":"Ferrara","year":"1997","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib127","first-page":"836","article-title":"Combination therapy with arbekacin and fosfomycin against postoperative severe mixed-pneumonia of MRSA in primary lung cancer patients [Japanese]","volume":"48","author":"Harada","year":"1995","journal-title":"Kyobu Geka"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib128","first-page":"804","article-title":"Clinical effect of the combined therapy of arbekacin and imipenem\/cilastatin against methicillin-resistant Staphylococcus aureus [Japanese]","volume":"47","author":"Hashimoto","year":"1994","journal-title":"Jpn J Antibiot"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib129","first-page":"798","article-title":"Combined therapy with arbekacin and fosfomycin for methicillin-resistant Staphylococcus aureus infections [Japanese]","volume":"47","author":"Kono","year":"1994","journal-title":"Jpn J Antibiot"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib130","first-page":"790","article-title":"Staggered intensive chemotherapy using arbekacin, fosfomycin and ceftazidime on polymicrobial infections involving MRSA [Japanese]","volume":"47","author":"Tanaka","year":"1994","journal-title":"Jpn J Antibiot"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib131","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1128\/AAC.00237-09","article-title":"In-vitro 24-hour time kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus","volume":"53","author":"Singh","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2010.03135.x_bib132","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/S0924-8579(09)70547-3","article-title":"Treatment options for skin and soft tissue infections caused by meticillin-resistant Staphylococcus aureus: oral vs. parenteral; home vs. hospital","volume":"34","author":"Esposito","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib133","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1476-0711-8-22","article-title":"Hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) in Italy","volume":"8","author":"Campanile","year":"2009","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib134","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ijantimicag.2005.09.003","article-title":"Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA)","volume":"26","author":"Itani","year":"2005","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl.7","key":"10.1111\/j.1469-0691.2010.03135.x_bib135","first-page":"S16","article-title":"Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to methicillin-resistant Staphylococcus aureus","volume":"14","author":"Itani","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib136","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib137","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/jac\/dkh088","article-title":"Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections","volume":"53","author":"Wilcox","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib138","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1128\/AAC.00262-07","article-title":"Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus","volume":"51","author":"Ruhe","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib139","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1086\/525536","article-title":"Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection","volume":"46","author":"Proctor","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib140","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.inf.0000073163.37519.ee","article-title":"Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children","volume":"22","author":"Martinez-Aguilar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib141","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1128\/JCM.02582-05","article-title":"Prevalence of inducible clindamycin resistance among community- and hospitalassociated Staphylococcus aureus isolates","volume":"44","author":"Patel","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib142","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ijantimicag.2008.10.014","article-title":"Oral antimicrobial options for the treatment of skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in the UK","volume":"33","author":"Enoch","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib143","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa043252","article-title":"Methicillin-resistant Staphylococcus aureus disease in three communities","volume":"352","author":"Fridkin","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib144","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1128\/AAC.37.6.1334","article-title":"Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim\u2013sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome","volume":"37","author":"Walsh","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib145","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/jac\/34.1.189","article-title":"A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients","volume":"34","author":"Muder","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib146","first-page":"2667","article-title":"Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers [Dutch]","volume":"152","author":"Wertheim","year":"2008","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib147","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jhin.2006.01.001","article-title":"Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities","volume":"1","author":"Coia","year":"2006","journal-title":"J Hosp Infect"},{"issue":"suppl 5","key":"10.1111\/j.1469-0691.2010.03135.x_bib148","doi-asserted-by":"crossref","first-page":"S386","DOI":"10.1086\/533595","article-title":"Management of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Cosgrove","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib149","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s001340000640","article-title":"Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia","volume":"27","author":"Dupont","year":"2001","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1378\/chest.122.1.262","article-title":"Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia","volume":"122","author":"Iregui","year":"2002","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib151","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1164\/ajrccm.156.1.9607030","article-title":"The value of routine microbial investigation in ventilator-associated pneumonia","volume":"156","author":"Rello","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib152","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/01.CCM.0000227655.41566.3E","article-title":"Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment","volume":"34","author":"Schramm","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib153","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1164\/ajrccm.165.7.2105078","article-title":"Ventilator-associated pneumonia","volume":"165","author":"Chastre","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib154","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1164\/ajrccm.165.1.2105077","article-title":"Role of serial routine microbiologic culture results in the initial management of ventilator-associated pneumonia","volume":"165","author":"Hayon","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/01.CCM.0000253404.69418.AA","article-title":"Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse","volume":"35","author":"Leone","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib156","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1378\/chest.127.2.589","article-title":"Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures","volume":"127","author":"Michel","year":"2005","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib157","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00134-007-0953-z","article-title":"Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia","volume":"34","author":"Depuydt","year":"2008","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib158","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/AAC.01070-08","article-title":"Early- and late-onset pneumonia: is this still a useful classification?","volume":"53","author":"Gastmeier","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib159","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1007\/s00134-005-2697-y","article-title":"Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria","volume":"31","author":"Giantsou","year":"2005","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib160","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1164\/ajrccm.159.4.9807050","article-title":"The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group","volume":"159","author":"Heyland","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib161","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1378\/chest.117.5.1434","article-title":"A comparative analysis of patients with early-onset vs. late-onset nosocomial pneumonia in the ICU setting","volume":"117","author":"Ibrahim","year":"2000","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib162","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/cc7119","article-title":"Determinants and impact of multidrug antibiotic resistance in pathogens causing ventilator-associated-pneumonia","volume":"12","author":"Depuydt","year":"2008","journal-title":"Crit Care"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib163","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0028-1119809","article-title":"The role of MRSA in healthcare-associated pneumonia","volume":"30","author":"Lam","year":"2009","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib164","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1378\/chest.104.4.1230","article-title":"Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia","volume":"104","author":"Rello","year":"1993","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib165","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1001\/archinte.168.20.2205","article-title":"Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia","volume":"168","author":"Shorr","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib166","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1164\/ajrccm.157.2.9705064","article-title":"Ventilator-associated pneumonia caused by potentially drug-resistant bacteria","volume":"157","author":"Trouillet","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib167","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1164\/ajrccm.160.2.9812034","article-title":"Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices","volume":"160","author":"Rello","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib168","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1086\/422997","article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection","volume":"39","author":"Davis","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib169","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1086\/501846","article-title":"Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use","volume":"22","author":"Garrouste-Orgeas","year":"2001","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib170","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1086\/345955","article-title":"Risk of methicillin-resistant Staphylococcus aureus infection after previous infection or colonization","volume":"36","author":"Huang","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib171","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1086\/529381","article-title":"Strain-relatedness of methicillin-resistant Staphylococcus aureus isolates recovered from patients with repeated infection","volume":"46","author":"Huang","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib172","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.amjmed.2007.07.034","article-title":"The risk of infection after nasal colonization with Staphylococcus aureus","volume":"121","author":"Safdar","year":"2008","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib173","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1086\/432056","article-title":"Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals","volume":"41","author":"MacDougall","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib174","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.3201\/eid1008.020694","article-title":"Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996\u20132000","volume":"10","author":"Monnet","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib175","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-2006-933677","article-title":"Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat","volume":"27","author":"Lam","year":"2006","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib176","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1086\/500319","article-title":"Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study","volume":"42","author":"Charbonneau","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib177","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3201\/eid1108.050116","article-title":"Pseudomonas aeruginosa, Staphylococcus aureus, and fluoroquinolone use","volume":"11","author":"MacDougall","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib178","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/588566","article-title":"Impact of an environmental cleaning intervention on the presence of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci on surfaces in intensive care unit rooms","volume":"29","author":"Goodman","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajic.2005.07.005","article-title":"Risk factors for ICU-acquired methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Oztoprak","year":"2006","journal-title":"Am J Infect Control"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib180","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1378\/chest.128.3.1414","article-title":"Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia","volume":"128","author":"DeRyke","year":"2005","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib181","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1164\/ajrccm.161.3.9904115","article-title":"Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin\/dalfopristin versus vancomycin. Nosocomial Pneumonia Group","volume":"161","author":"Fagon","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib182","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1086\/318486","article-title":"Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study","volume":"32","author":"Rubinstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib183","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0885066603256012","article-title":"Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis","volume":"18","author":"Baughman","year":"2003","journal-title":"J Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib184","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cll.2004.03.009","article-title":"Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections","volume":"24","author":"Andes","year":"2004","journal-title":"Clin Lab Med"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib185","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/ajhp\/57.suppl_2.S4","article-title":"Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus","volume":"57","author":"Moise","year":"2000","journal-title":"Am J Health Syst Pharm"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib186","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib187","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib188","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib189","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib190","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/jac\/dki355","article-title":"Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies","volume":"56","author":"Shorr","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib191","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1086\/340353","article-title":"Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections","volume":"34","author":"Stevens","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib192","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.amjsurg.2004.08.045","article-title":"Linezolid eradicates MRSA better than vancomycin from surgical-site infections","volume":"188","author":"Weigelt","year":"2004","journal-title":"Am J Surg"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib193","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs. vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib194","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1128\/AAC.49.6.2260-2266.2005","article-title":"Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections","volume":"49","author":"Weigelt","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib195","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/dkh048","article-title":"Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study","volume":"53","author":"Cepeda","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib196","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib197","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jac\/dkn329","article-title":"Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"62","author":"Lodise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib198","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00134-002-1358-7","article-title":"Clinical experience with quinupristin\u2013dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci","volume":"28","author":"Sander","year":"2002","journal-title":"Intensive Care Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib199","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1086\/533441","article-title":"Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia","volume":"46","author":"Pertel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib200","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib201","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2165\/00003495-200767100-00008","article-title":"Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia","volume":"67","author":"Hair","year":"2007","journal-title":"Drugs"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib202","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ccc.2007.12.010","article-title":"The use of daptomycin for Staphylococcus aureus infections in critical care medicine","volume":"24","author":"Alder","year":"2008","journal-title":"Crit Care Clin"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib203","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4103\/0022-3859.48443","article-title":"Tigecycline","volume":"55","author":"Bhattacharya","year":"2009","journal-title":"J Postgrad Med"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib204","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/jac\/dkm541","article-title":"Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit","volume":"61","author":"Swoboda","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib205","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib206","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in nonvancomycin-intermediate Staphylococcus aureus (VISA), vancomycinsusceptible clinical methicillin-resistant Staphylococcus aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib207","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1086\/421092","article-title":"Accessory gene regulator group II polymor-phism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy","volume":"38","author":"Moise-Broder","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"suppl 2","key":"10.1111\/j.1469-0691.2010.03135.x_bib208","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0924-8579(08)70002-5","article-title":"Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus","volume":"31","author":"Gould","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib209","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1128\/AAC.47.10.3040-3045.2003","article-title":"Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods","volume":"47","author":"Liu","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib210","first-page":"565","article-title":"Staphylococcus aureus resistant to vancomycin\u2013-United States 2002","volume":"51","author":"CDC","year":"2002","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib211","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijantimicag.2006.12.011","article-title":"Surveillance analysis of decreasing susceptibility of Staphylococcus aureus to vancomycin using a mathematical model","volume":"29","author":"Rodriguez-Morales","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib212","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib213","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/JCM.39.7.2439-2444.2001","article-title":"Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides","volume":"39","author":"Walsh","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib214","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/S0149-2918(03)80118-2","article-title":"Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia","volume":"25","author":"Wunderink","year":"2003","journal-title":"Clin Ther"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib215","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1468-1331.2005.01001.x","article-title":"Clinical experience with linezolid for the treatment of central nervous system infections","volume":"12","author":"Rupprecht","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib216","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1345\/aph.1H307","article-title":"Linezolid for the treatment of patients with central nervous system infection","volume":"41","author":"Ntziora","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib217","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1378\/chest.08-2169","article-title":"Effect of linezolid compared with glycopeptides in methicillin-resistant Staphylococcus aureus severe pneumonia in piglets","volume":"135","author":"Luna","year":"2009","journal-title":"Chest"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib218","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s15010-007-6211-z","article-title":"Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid","volume":"35","author":"Kessler","year":"2007","journal-title":"Infection"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib219","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3171\/JNS-07\/09\/0651","article-title":"Successful treatment of methicillin-resistant Staphylococcus aureus meningitis using linezolid without removal of intrathecal infusion pump. Case report","volume":"107","author":"Kallweit","year":"2007","journal-title":"J Neurosurg"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib220","first-page":"11","article-title":"Daptomycin (Cubicin) for skin and soft tissue infections","volume":"46","year":"2004","journal-title":"Med Lett Drugs Ther"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib221","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10096-002-0753-x","article-title":"Efficacy and safety of linezolid in the treatment of skin and soft tissue infections","volume":"21","author":"Hau","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib222","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/109629603764655290","article-title":"Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial","volume":"4","author":"Li","year":"2003","journal-title":"Surg Infect (Larchmt)"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib223","first-page":"813","article-title":"Daptomycin for soft tissue infection and neutropenia in a myelogenous leukemia patient who failed prior vancomycin therapy","volume":"6","author":"Sakoulas","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2010.03135.x_bib224","first-page":"iii15","article-title":"Daptomycin: rationale and role in the management of skin and soft tissue infections","volume":"62","author":"Seaton","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib225","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1128\/AAC.44.12.3408-3413.2000","article-title":"Randomized comparison of linezolid (PNU-100766) versus oxacillin\u2013dicloxacillin for treatment of complicated skin and soft tissue infections","volume":"44","author":"Stevens","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib226","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2010.03135.x_bib227","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,25]],"date-time":"2019-05-25T22:24:17Z","timestamp":1558823057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14616219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":227,"alternative-id":["S1198743X14616219"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2010.03135.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}